BFM
ELVN icon

Boothbay Fund Management’s Enliven Therapeutics ELVN Stock Holding History

Boothbay Fund Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,400
Closed -$956K – 2355
2026
Q1 		$956K Buy
+24,400
New +$676K 0.01% 976

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Boothbay Fund Management's ELVN Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 39,031 shares worth $1.98M. The stake represents 0.03% of the portfolio and ranks #725 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in ELVN as recently as Q1 2025.

Boothbay Fund Management first reported a position in ELVN in Q2 2024 and has held it in 5 quarters since. The position peaked at $3.64M in Q2 2024. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Boothbay Fund Management held 39,031 shares of Enliven Therapeutics worth $1.98M as of Q2 2026.
  • Enliven Therapeutics was a new Boothbay Fund Management position in Q2 2026.
  • Enliven Therapeutics made up 0.03% of Boothbay Fund Management's portfolio in Q2 2026, its #725 holding.
  • Boothbay Fund Management first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Boothbay Fund Management's Enliven Therapeutics position peaked at $3.64M in Q2 2024.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.